New Zealand markets closed

Pacific Biosciences of California, Inc. (PACB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.7500+0.0300 (+0.81%)
At close: 04:00PM EDT
3.7981 +0.05 (+1.28%)
After hours: 07:52PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close3.7200
Open3.7600
Bid3.7400 x 1800
Ask3.7700 x 3600
Day's range3.6800 - 3.8900
52-week range3.4600 - 14.5500
Volume6,461,957
Avg. volume8,812,942
Market cap1.005B
Beta (5Y monthly)1.87
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • PR Newswire

    Estonia National Biobank Selects PacBio to Sequence 10,000 Whole Genomes

    PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that the University of Tartu, host of Estonia's National Biobank, has chosen the Revio HiFi sequencing system to sequence 10,000 whole human genomes and unlock new insights from its populational health data. The announcement follows funding from the European Commission and the Estonian government to help Estonia adopt personalized medicine at scale and adapt public health systems to

  • PR Newswire

    PacBio Grants Equity Incentive Award to New Employee

    PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option (the "Option") covering an aggregate of 79,600 shares of PacBio common stock and restricted stock units ("RSUs") covering 39,800 shares of PacBio common stock to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the "2020 Inducement Plan

  • PR Newswire

    PacBio Announces PureTarget™ Repeat Expansion Panel, Expanding its Portfolio of End-to-End Clinical Research Solutions

    PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the PureTarget repeat expansion panel, a new solution designed to enable the comprehensive analysis of 20 genes associated with serious neurological disorders, including challenging-to-sequence genes with tandem repeat expansions. The new long-read workflow can minimize iterative analysis using legacy technology, and reduce the time needed to identify disease-causing variants and ass